首页 | 官方网站   微博 | 高级检索  
     


A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer
Affiliation:1. Englander Institute for Precision Medicine, Weill Cornell Medical Center, New York, USA;2. Montreal Cancer Institute, Montreal University Hospital Center (CHUM), Montreal, QC, Canada;3. Knight Cancer Institute, Oregon Health and Science University and VA Portland Health Care System, Portland, USA;4. Department of Oncology, Rambam Health Care Center, Haifa, Israel;5. Department of Oncology, Wayne State University/Karmanos Cancer Institute, Detroit, USA;6. Division of Nuclear Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada;7. Institute of Oncology, Rabin Medical Center-Davidoff Cancer Center, Petah Tikva, Israel;8. Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, Australia;9. Department of Medical Oncology, The Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, Australia;10. Department of Medicine, Monash University, Melbourne, Australia;11. Eastern Health, Melbourne, Australia;12. Clinical Statistics Oncology, Bayer HealthCare Pharmaceutical Inc, Whippany, USA;13. Global Clinical Development, Bayer Consumer Care AG, Basel, Switzerland;14. Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, USA
Abstract:
Keywords:bone metastases  mCRPC  radium-223 dose  safety  symptomatic skeletal events
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号